POTASSIUM CITRATE MIXTURE Solution Ref.[9201] Active ingredients: Potassium citrate

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2015  Publisher: L.C.M. Ltd., Linthwaite Laboratories, Huddersfield, HD7 5QH, England

Contraindications

Contraindicated in hyperkalaemia, renal dysfunction, ventricular arrhythmics and Addison’s Disease.

Special warnings and precautions for use

Potassium Citrate Mixture provides symptomatic relief only and is not anti-bacterial. Effective anti-bacterial therapy should be co-prescribed. It should be used with caution when renal or cardiac dysfunction is present.

Labels to state: if symptoms persist consult your doctor. Discard any unused mixture 2 months after opening.

Use with caution in the elderly.

Interaction with other medicinal products and other forms of interaction

Concurrent administration of potassium-containing drugs, potassium sparing diuretics or other drugs that increase potassium levels (e.g. ACE inhibitors, ciclosporin, aliskiren) may lead to hyperkalaemia. May interact with cardiac glycosides. Citrates alkalinise the urine and thus may alter the urinary excretion of a number of drugs. This may lead to increased renal clearance of acidic drugs, such as salicylates, tetracylines and barbiturates, and prolongation of the half-life of basic drugs, such as sympathomimetics and stimulants. Particularly noteworthy is the diminished anti-bacterial activity of nitrofurantoin and methenamine.

Pregnancy and lactation

No adverse effects are anticipated at recommended doses when used for initial symptomatic relief only. Treatment with potassium citrate mixture is adjunctive and secondary to anti-bacterial treatment of urinary tract infection.

Effects on ability to drive and use machines

No effect on mental alertness.

Undesirable effects

Mild nausea and occasionally vomiting may occur due to gastric irritation. Other side effects are those due to hyperkalaemia (if this occurs).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Incompatibilities

Incompatible with calcium and strontium salts.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.